QC
BNTC icon

Quadrature Capital’s Benitec Biopharma BNTC Stock Holding History

Quadrature Capital’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
15,371
-2,714
-15% -$32.2K ﹤0.01% 1350
2026
Q1 		$193K Sell
18,085
-13,396
-43% -$155K ﹤0.01% 1130
2025
Q4 		$424K Buy
+31,481
New +$435K ﹤0.01% 741

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Quadrature Capital's BNTC Position: Q2 2026 in Review

Quadrature Capital reduced its Benitec Biopharma (BNTC) stake by 15% in Q2 2026, selling an estimated $32.2K and leaving 15,371 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Quadrature Capital first reported a position in BNTC in Q4 2025 and has held it in 3 quarters since. The position peaked at $424K in Q4 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Quadrature Capital held 15,371 shares of Benitec Biopharma worth $206K as of Q2 2026.
  • Quadrature Capital sold 2,714 Benitec Biopharma shares in Q2 2026, an estimated $32.2K.
  • Benitec Biopharma made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1350 holding.
  • Quadrature Capital first reported a position in Benitec Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Benitec Biopharma position peaked at $424K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.